BioCentury | May 7, 2007
Company News

Vical gene/cell therapy news

...technology that expresses exogenous polynucleotide sequences in vertebrates. GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.) and PowderJect Pharmaceuticals plc...
...did not appeal within 30 days of the decision, the rulings became final. In 2003, PowderJect...
BioCentury | Oct 16, 2006
Strategy

Pfizer goes for the gold

...number of hands before ending up as part of Oxford BioSciences Ltd., which eventually became PowderJect Pharmaceuticals plc...
...Chiron, which is now part of Novartis AG (NVS; SWX:NOVN, Basel, Switzerland), then acquired PowderJect...
...delivery methods. Despite these advantages, according to Dix, Chiron decided not to allocate resources towards PowderJect's...
BioCentury | Oct 9, 2006
Company News

Oxxon, Bavarian Nordic A/, Danisco, Novartis, Oxford BioMedica, sanofi-aventis, Therion infectious news

...by BAVA, SAN, OXB, Therion, Danisco subsidiary Genencor International Inc. (Palo Alto, Calif.), and NVS's PowderJect Pharmaceuticals plc...
BioCentury | May 22, 2006
Strategy

CAT nipped

...past two years, Celltech has been taken over by UCB Group (Euronext:UCB, Brussels, Belgium), while PowderJect Pharmaceuticals plc...
BioCentury | Oct 3, 2005
Strategy

Money + compounds = fit

...inflammatory and infectious diseases, as well as oncology. AlgoRx acquired ALGRX 3268 in 2002 from PowderJect Pharmaceuticals plc...
BioCentury | Sep 5, 2005
Strategy

Novartis loads up

...$563 million, a 12% increase from 2003. On the other hand, CHIR's 2003 acquisition of PowderJect Pharmaceuticals plc...
BioCentury | May 23, 2005
Finance

Europe's Iceberg 2005

...Qiagen N.V. (FSE:QIA; QGEN, Venlo, the Netherlands), U.K. drug delivery plays Galen Holdings plc and PowderJect Pharmaceuticals plc...
...including SHP and QIA, which have market caps of $5.1 billion and $1.8 billion, respectively. Powderject...
BioCentury | Feb 10, 2005
Financial News

AlgoRx amends IPO

...III testing as a local anesthetic. The compound is delivered using needle-free technology licensed from PowderJect...
BioCentury | Dec 20, 2004
Strategy

Kicking Chiron when it's down

...doses next year, but that it's too soon to say what total capacity will be. PowderJect...
...dejection The manufacturing debacle has jeopardized CHIR's ability to monetize its July 2003 acquisition of PowderJect Pharmaceuticals plc...
...Total Fluvirin sales in 2003 were $129 million, and total sales for products acquired with PowderJect...
BioCentury | Nov 29, 2004
Financial News

AlgoRx files for IPO

...III testing as a local anesthetic. The compound is delivered using needle-free technology licensed from PowderJect...
Items per page:
1 - 10 of 228
BioCentury | May 7, 2007
Company News

Vical gene/cell therapy news

...technology that expresses exogenous polynucleotide sequences in vertebrates. GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.) and PowderJect Pharmaceuticals plc...
...did not appeal within 30 days of the decision, the rulings became final. In 2003, PowderJect...
BioCentury | Oct 16, 2006
Strategy

Pfizer goes for the gold

...number of hands before ending up as part of Oxford BioSciences Ltd., which eventually became PowderJect Pharmaceuticals plc...
...Chiron, which is now part of Novartis AG (NVS; SWX:NOVN, Basel, Switzerland), then acquired PowderJect...
...delivery methods. Despite these advantages, according to Dix, Chiron decided not to allocate resources towards PowderJect's...
BioCentury | Oct 9, 2006
Company News

Oxxon, Bavarian Nordic A/, Danisco, Novartis, Oxford BioMedica, sanofi-aventis, Therion infectious news

...by BAVA, SAN, OXB, Therion, Danisco subsidiary Genencor International Inc. (Palo Alto, Calif.), and NVS's PowderJect Pharmaceuticals plc...
BioCentury | May 22, 2006
Strategy

CAT nipped

...past two years, Celltech has been taken over by UCB Group (Euronext:UCB, Brussels, Belgium), while PowderJect Pharmaceuticals plc...
BioCentury | Oct 3, 2005
Strategy

Money + compounds = fit

...inflammatory and infectious diseases, as well as oncology. AlgoRx acquired ALGRX 3268 in 2002 from PowderJect Pharmaceuticals plc...
BioCentury | Sep 5, 2005
Strategy

Novartis loads up

...$563 million, a 12% increase from 2003. On the other hand, CHIR's 2003 acquisition of PowderJect Pharmaceuticals plc...
BioCentury | May 23, 2005
Finance

Europe's Iceberg 2005

...Qiagen N.V. (FSE:QIA; QGEN, Venlo, the Netherlands), U.K. drug delivery plays Galen Holdings plc and PowderJect Pharmaceuticals plc...
...including SHP and QIA, which have market caps of $5.1 billion and $1.8 billion, respectively. Powderject...
BioCentury | Feb 10, 2005
Financial News

AlgoRx amends IPO

...III testing as a local anesthetic. The compound is delivered using needle-free technology licensed from PowderJect...
BioCentury | Dec 20, 2004
Strategy

Kicking Chiron when it's down

...doses next year, but that it's too soon to say what total capacity will be. PowderJect...
...dejection The manufacturing debacle has jeopardized CHIR's ability to monetize its July 2003 acquisition of PowderJect Pharmaceuticals plc...
...Total Fluvirin sales in 2003 were $129 million, and total sales for products acquired with PowderJect...
BioCentury | Nov 29, 2004
Financial News

AlgoRx files for IPO

...III testing as a local anesthetic. The compound is delivered using needle-free technology licensed from PowderJect...
Items per page:
1 - 10 of 228